alendronate has been researched along with Postpoliomyelitis Syndrome in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Postpoliomyelitis Syndrome: A syndrome characterized by new neuromuscular symptoms that occur at least 15 years after clinical stability has been attained in patients with a prior history of symptomatic poliomyelitis. Clinical features include new muscular weakness and atrophy of the limbs, bulbar innervated musculature, and muscles of respiration, combined with excessive fatigue, joint pain, and reduced stamina. The process is marked by slow progression and periods of stabilization. (From Ann NY Acad Sci 1995 May 25;753:68-80)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, A | 1 |
| Kremer, R | 1 |
| Weiss, DR | 1 |
| Benedetti, A | 1 |
| Haziza, M | 1 |
| Trojan, DA | 1 |
1 other study available for alendronate and Postpoliomyelitis Syndrome
| Article | Year |
|---|---|
Response of postpoliomyelitis patients to bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Stud | 2010 |